The agreement, reached on the sidelines of the French Healthcare Business Forum (FHBF 2026), also provides for the training and secondment of Egyptian cardiology and oncology physicians to specialised medical centres in France, according to a statement by EHA.
Under the protocol, the two sides will cooperate to develop oncology services across the Authority’s facilities, build the capacity of multidisciplinary medical teams, support clinical research, and deploy digital solutions to improve medical decision-making and the quality and efficiency of care within Egypt’s Universal Health Insurance System.
Authority Chairman Ahmed El-Sobky said the partnership aims to localise the manufacture of oncology treatments and innovative medicines for rare diseases, while strengthening evidence-based treatment pathways and accelerating digital transformation in oncology patient data management to ensure integrated and sustainable healthcare delivery.
As part of the agreement, Al-Nasr Specialized Hospital in Port Said will implement an intensive care programme for paediatric cancer patients, with Servier providing expertise aligned with the latest international treatment protocols to improve clinical outcomes and specialised care standards.
The move comes as the government intensifies efforts to upgrade oncology services nationwide, with Health Minister Khaled Abdel-Ghaffar recently directing officials to prepare a plan to enlist French administrative and nursing teams from Gustave Roussy at Gustave Roussy International–Egypt.
Servier executives said the company was proud to expand cooperation with the General Authority for Healthcare, pledging support for the development of Egypt’s oncology care system, the transfer of international expertise, and broader access to innovative medicines in line with public health priorities and the sustainability of the Universal Health Insurance System.
The Authority said it would continue to expand high-quality international partnerships to support pharmaceutical localisation, medical innovation, and the delivery of specialised, safe, and sustainable healthcare services nationwide.
Founded in 1954, Servier is a privately owned, research-driven French pharmaceutical group with a strong international footprint spanning more than 150 countries.
Headquartered in Suresnes, near Paris, the company focuses on cardiology and metabolic diseases, oncology, neuroscience, and immuno-inflammatory and rare diseases.
Servier reinvests a significant share of its revenues into research and development, with oncology designated as a core strategic priority following major investments in targeted therapies, precision medicine, and clinical research platforms.
Short link: